Related Experiment Video

Updated: Nov 27, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.5K

Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies

Kathleen Sullivan1, Lynne S Kaminer1, David L Grinblatt1

  • 1NorthShore University HealthSystem, Evanston, IL.

JCO Oncology Practice
|December 3, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.7K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.0K

Related Experiment Videos

Last Updated: Nov 27, 2025

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

2.5K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.7K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.0K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

881
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
881

Articles linked to this work by shared authors, journal, and citation graph.

Reframing Women's Health in Kidney Disease: Sex Differences, Gender Disparities, and Clinical Imperatives - Introduction to a Special Series.

Kidney360·2026

Cardiovascular-Kidney-Metabolic Syndrome in Women: Bridging Nephrology and the Female Cardiometabolic Disparity.

Kidney360·2026

Monovalent Anti-FcγRIIA Antibody Blocks Immune-Mediated Thrombocytopenia and Thrombosis With Minimal Adverse Side Effects in Mice.

Arteriosclerosis, thrombosis, and vascular biology·2026

Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026

Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia.

Blood·2026

Differentiating pathogenic from bystander autoantibodies in immune thrombocytopenia using intact glycoproteindeficient megakaryocytes.

Haematologica·2025

Pancreatic Cancer Cachexia: Integrating Mechanistic Insights With Clinical Management.

JCO oncology practice·2026

Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer.

JCO oncology practice·2026

Racial Disparities in the Management of Myeloma Bone Disease: A Retrospective Cohort Study.

JCO oncology practice·2026

Contemporary Patterns of Medicare Part B Spending on Immune Checkpoint Inhibitors (2018-2022).

JCO oncology practice·2026

Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone Therapy.

JCO oncology practice·2026

Financial Toxicity and Quality of Life After Bone Marrow Transplant: A Longitudinal, Prospective Study.

JCO oncology practice·2026

Inferior vena cava hyperechoic structure in a patient with cardiac myxoma: a surgical case report and literature review.

General thoracic and cardiovascular surgery cases·2026

The Relationship Between Hospital Immunotherapy Volume and Treatment and Survival of Advanced Cutaneous Melanoma.

The Journal of surgical research·2026

Primary pulmonary mucosa-associated lymphoid tissue lymphoma presenting as a right hilar mass: A case report.

Medicine·2026

Cholecystogastric fistula masquerading as gastrointestinal stromal tumour: Unusual presentation of gallbladder adenomyomatosis - a case report.

Medicine·2026

Cancer immunoediting in the melanoma tumor microenvironment: from immune elimination to therapeutic resistance.

Frontiers in immunology·2026

Immune remodeling of tumor-draining lymph nodes: mechanistic determinants of checkpoint blockade responsiveness.

Frontiers in immunology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us